Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy

Prostate cancer is prevalent in the United States, with approximately 230,110 new cases and
29,900 deaths in 2004. Approximately 30% of new cases will be clinical stage T3 when they
are diagnosed. This is a stage in which there is high probability that the cancer has spread
beyond the prostate gland itself, making it much more difficult to treat. In these cases,
when surgery is done by itself and the prostate is removed, it is still very likely that
some cancer that has spread beyond the prostate remains and will get worse. Radiation
applied to the prostate also does not work well on tumors that have spread beyond the
prostate. Even surgery and radiation combined have not eliminated the problems caused by
prostate cancer that has spread into the tissue outside the prostate itself.

New treatments are needed to deal with prostate cancer at this more serious stage. Study
doctors believe that it might be possible to shrink the prostate cancer using a new drug
called SUO11248 or Sunitinib. After the patients take the drug, study doctors believe the
cancer will shrink back to within the prostate, and they can then surgically remove the
prostate and all the cancer. Patients on this study also will be given increasing doses of
Sunitinib to find out how much of the drug can be given safely.